4.6 Article

Female Reproductive Factors, Menopausal Hormone Use, and Parkinson's Disease

Journal

MOVEMENT DISORDERS
Volume 29, Issue 7, Pages 889-896

Publisher

WILEY-BLACKWELL
DOI: 10.1002/mds.25771

Keywords

reproductive factors; Parkinson's disease; cohort studies; menopausal hormone therapy

Funding

  1. NIH, the National Institute Neurological Disorders and Stroke [R01-NS060722, U01-NS082151]
  2. NIH, National Institute of Environmental Health Sciences [Z01-ES-101986]
  3. NIH, National Cancer Institute [Z01 CP010196-02]

Ask authors/readers for more resources

The objective of this study was to examine the associations of reproductive factors and exogenous hormone use with risk of Parkinson's disease (PD) among postmenopausal women. The study comprised 119,166 postmenopausal women aged 50 to 71 years in the NIH-AARP Diet and Health Study, who completed a baseline questionnaire in 1995-1996 and a follow-up survey in 2004-2006. A total of 410 selfreported PD diagnoses were identified between 1995 and 2006. Multivariate odds ratios (ORs) and 95% confidence intervals (CIs) were derived from logistic regression models. PD risk was not significantly associated with female reproductive factors including age at menarche, age at first live birth, parity, and age at menopause. For example, compared with women with natural menopause at age 50 to 54 years, the ORs were 1.18, (95% CI, 0.78-1.79) for women with natural menopause aged <45, 1.19 (95% CI, 0.88-1.61) for those aged 45 to 49, and 1.33 (95% CI, 0.91-1.93) for those aged 55 or older. We found that oral contraceptive use for >= 10 years (vs. never used) was associated with lower PD risk (OR, 0.59; 95% CI, 0.38-0.92), but shorter use showed no association. Use of menopausal hormone therapy showed inconsistent results. Compared with non-hormone users at baseline, current hormone users for <5 years showed a higher risk of PD (OR, 1.52; 95% CI, 1.11-2.08). However, no associations were observed for past hormone users or current users of >= 5 years. Overall, this large prospective study provides little support for an association between female reproductive factors and PD risk. Our findings on long-term oral contraceptive use and current hormone therapy warrant further investigations. (C) 2013 International Parkinson and Movement Disorder Society

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Associations between serum glucose, insulin, insulin resistance and the risk of incident primary liver cancer or chronic liver disease mortality: a nested case-control study

Jian Yin, Neal D. Freedman, Yiwei Liu, Sanford M. M. Dawsey, Huan Yang, Philip R. R. Taylor, Liangyu Yin, Bin Liu, Jianfeng Cui, Jinhu Fan, Wen Chen, Youlin Qiao, Christian C. C. Abnet

Summary: This study found that serum insulin and HOMA-IR may be risk factors for the development of primary liver cancer (PLC) or chronic liver disease (CLD) death. In HBV-positive patients, glucose was also associated with an increased risk of these diseases.

BRITISH JOURNAL OF CANCER (2023)

Article Obstetrics & Gynecology

Urinary phenol concentrations and fecundability and early pregnancy loss

Ana K. Rosen Vollmar, Clarice R. Weinberg, Donna D. Baird, Allen J. Wilcox, Antonia M. Calafat, Nicole C. Deziel, Caroline H. Johnson, Anne Marie Z. Jukic

Summary: Urinary phenol concentrations of 2,5-dichlorophenol were associated with an increased odds of early pregnancy loss, while higher concentrations of butylparaben and triclosan were associated with an increase in fecundability. This study is the first to investigate the associations between phenol exposure and fecundability and early pregnancy loss using repeated pooled measures, providing important insights for future research on reproductive health.

HUMAN REPRODUCTION (2023)

Article Multidisciplinary Sciences

Inflated expectations: Rare-variant association analysis using public controls

Jung Kim, Danielle M. Karyadi, Stephen W. Hartley, Bin Zhu, Mingyi Wang, Dongjing Wu, Lei Song, Gregory T. Armstrong, Smita Bhatia, Leslie L. Robison, Yutaka Yasui, Brian Carter, Joshua N. Sampson, Neal D. Freedman, Alisa M. Goldstein, Lisa Mirabello, Stephen J. Chanock, Lindsay M. Morton, Sharon A. Savage, Douglas R. Stewart

Summary: The use of publicly available sequencing datasets as controls in rare variant disease association studies can increase the risk of false-positive discoveries. This study systematically investigated the factors that contribute to false-positive discoveries using both public controls and datasets sequenced in their own laboratory. The results showed that using the same variant caller and filtering pipelines significantly reduced the inflation of test statistics. However, differences in library prep kits and sequencers as well as joint vs. separate variant-calling of cases and controls did not affect the false-positive rate. This highlights the risks associated with using public controls and suggests the potential of cloud-based computing to mitigate these issues.

PLOS ONE (2023)

Article Multidisciplinary Sciences

GWAS Explorer: an open-source tool to explore, visualize, and access GWAS summary statistics in the PLCO Atlas

Mitchell J. Machiela, Wen-Yi Huang, Wendy Wong, Sonja I. Berndt, Joshua Sampson, Jonas De Almeida, Mustapha Abubakar, Jada Hislop, Kai-Ling Chen, Casey Dagnall, Norma Diaz-Mayoral, Mary Ferrell, Michael Furr, Alex Gonzalez, Belynda Hicks, Aubrey K. Hubbard, Amy Hutchinson, Kevin Jiang, Kristine Jones, Jia Liu, Erikka Loftfield, Jennifer Loukissas, Jerome Mabie, Shannon Merkle, Eric Miller, Lori M. Minasian, Ellen Nordgren, Brian Park, Paul Pinsky, Thomas Riley, Lorena Sandoval, Neeraj Saxena, Aurelie Vogt, Jiahui Wang, Craig Williams, Patrick Wright, Meredith Yeager, Bin Zhu, Claire Zhu, Stephen J. Chanock, Montserrat Garcia-Closas, Neal D. Freedman

Summary: The PLCO Cancer Screening Trial is a prospective cohort study that developed the PLCO Atlas Project, a large resource for GWAS. Genotyping was performed on participants with available DNA, and GWAS were conducted using a custom pipeline. The PLCO Atlas GWAS Explorer website, with APIs and SDKs, allows for exploration, visualization, and open data access. It currently hosts association data for 90 traits and >78 million genomic markers, focusing on cancer-related phenotypes. The PLCO Atlas is a FAIR resource for cancer research and genetic epidemiology.

SCIENTIFIC DATA (2023)

Article Oncology

Biomarkers of Tobacco Carcinogenesis in Diverse Populations: Challenges and Opportunities

Arash Etemadi, Christian C. Abnet, Sanford M. Dawsey, Neal D. Freedman

Summary: Biomarkers can provide unique information about cancer risk factors by measuring the internal dose of carcinogens. Smoke-related biomarkers, including tobacco-specific biomarkers and those from exposure to tobacco and non-tobacco pollutants, are commonly studied in relation to cancer. Biomonitoring is superior to self-reported exposure assessment and will continue to be essential to cancer research.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2023)

Article Oncology

Stressful Life Events, Social Support, and Incident Breast Cancer by Estrogen Receptor Status

Wayne R. Lawrence, Jasmine A. McDonald, Faustine Williams, Meredith S. Shiels, Neal D. Freedman, Ziqiang Lin, Jared W. Magnani

Summary: Chronic stress is hypothesized to be associated with breast cancer, but previous studies have shown mixed results. This study examined the association between self-reported stressful life events and incident breast cancer in postmenopausal women, taking into account estrogen receptor (ER) status and social support. The results showed that there was no relationship between stressful life events and ER-positive breast cancer, but there was an increased risk of ER-negative breast cancer in women with higher levels of stressful life events. This association was stronger in widowed women. Social support did not modify the relationship between stressful life events and ER-negative breast cancer.

CANCER PREVENTION RESEARCH (2023)

Article Oncology

Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

Vicky C. C. Chang, Jongeun Rhee, Sonja I. I. Berndt, Steven C. C. Moore, Neal D. D. Freedman, Rena R. R. Jones, Debra T. T. Silverman, Gretchen L. L. Gierach, Jonathan N. N. Hofmann, Mark P. P. Purdue

Summary: In this nested case-control study, prediagnostic serum levels of PFOS and PFOA were found to be associated with breast cancer risk, particularly for hormone receptor-positive tumors, providing evidence of a possible positive association.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Oncology

Cancer mortality rates by racial and ethnic groups in the United States, 2018-2020

Anika T. Haque, Amy Berrington de Gonzalez, Yingxi Chen, Emily A. Haozous, Maki Inoue-Choi, Wayne R. Lawrence, Jennifer K. McGee-Avila, Anna M. Napoles, Eliseo J. Perez-Stable, Kekoa Taparra, Jacqueline B. Vo, Neal D. Freedman, Meredith S. Shiels

Summary: The study estimated cancer death rates among different racial and ethnic groups in the United States from 2018 to 2020. The results found significant disparities in cancer death rates, with the highest rates observed among Black individuals and Native Hawaiian and Pacific Islander (NHPI) individuals. Separating NHPI and Asian individuals revealed large differences in cancer mortality between the two groups that were previously combined in vital statistics data.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Article Oncology

Lung cancer risk discrimination of prediagnostic proteomics measurements compared with existing prediction tools

Xiaoshuang Feng, Wendy Yi-Ying Wu, Justina Ucheojor Onwuka, Zahra Haider, Karine Alcala, Karl Smith-Byrne, Hana Zahed, Florence Guida, Renwei Wang, Julie K. Bassett, Victoria Stevens, Ying Wang, Stephanie Weinstein, Neal D. Freedman, Chu Chen, Lesley Tinker, Therese Haugdahl Nost, Woon-Puay Koh, David Muller, Sandra M. Colorado-Yohar, Rosario Tumino, Rayjean J. Hung, Christopher Amos, Xihong Lin, Xuehong Zhang, Alan A. Arslan, Maria-Jose Sanchez, Elin Pettersen Sorgjerd, Gianluca Severi, Kristian Hveem, Paul Brennan, Arnulf Langhammer, Roger L. Milne, Jian-Min Yuan, Beatrice Melin, Mikael Johansson, Hilary A. Robbins, Mattias Johansson

Summary: This study aimed to develop a proteomics-based risk model for lung cancer and compare its performance with a smoking-based risk model and a commercially available autoantibody biomarker test. We conducted a case-control study in 6 prospective cohorts, involving 624 lung cancer participants and 624 smoking-matched cancer free participants. The protein-based risk model showed promise in predicting incident lung cancer and outperformed the standard risk prediction model and the commercialized EarlyCDT-Lung.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Article Biochemistry & Molecular Biology

Genetically adjusted PSA levels for prostate cancer screening

Linda Kachuri, Thomas J. Hoffmann, Yu Jiang, Sonja I. Berndt, John P. Shelley, Kerry R. Schaffer, Mitchell J. Machiela, Neal D. Freedman, Wen-Yi Huang, Shengchao A. Li, Ryder Easterlin, Phyllis J. Goodman, Cathee Till, Ian Thompson, Hans Lilja, Stephen K. Van Den Eeden, Stephen J. Chanock, Christopher A. Haiman, David V. Conti, Robert J. Klein, Jonathan D. Mosley, Rebecca E. Graff, John S. Witte

Summary: Prostate-specific antigen (PSA) screening for prostate cancer remains controversial due to overdiagnosis and overtreatment. However, accounting for genetic determinants of PSA variation may improve screening accuracy.

NATURE MEDICINE (2023)

Article Oncology

Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047

Meredith S. Shiels, Stanley Lipkowitz, Nicole G. Campos, Mark Schiffman, John T. Schiller, Neal D. Freedman, Amy Berrington de Gonzalez

Summary: President Biden and First Lady Dr. Biden have reignited the Cancer Moonshot with the goal of reducing age-standardized cancer mortality rates by at least 50% in the United States over the next 25 years. From 2000 to 2019, overall cancer death rates declined, driven by significant decreases in lung, colorectal, and breast cancer mortality. However, progress for other cancer types was less promising, highlighting the need for new strategies. Achieving the Moonshot goal requires maintaining or accelerating progress in controlling lung, colorectal, and breast cancer deaths, and developing new approaches for prostate, liver, pancreatic, and other cancers.

CANCER DISCOVERY (2023)

Meeting Abstract Oncology

Association of genetic ancestry with lung-cancer risk in White and Black eversmokers.

Courtney D. Dill, Dontray Trump, Rebecca Landy, Li Cheung, Wen-Yi Huang, Sonja Berndt, Neal Freedman, Hormuzd Katki

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2023)

Meeting Abstract Oncology

Association of genetic ancestry with lung-cancer risk in White and Black ever-smokers

Courtney D. Dill, Dontray Trump, Rebecca Landy, Li Cheung, Wen-Yi Huang, Sonja Berndt, Neal Freedman, Hormuzd Katki

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2023)

Meeting Abstract Oncology

Association of genetic ancestry with lung-cancer risk in White and Black ever-smokers

Courtney D. Dill, Dontray Trump, Rebecca Landy, Li Cheung, Wen-Yi Huang, Sonja Berndt, Neal Freedman, Hormuzd Katki

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2023)

Article Oncology

Multivitamin use and all-cause and cause-specific mortality in cancer survivors

Yikyung Park, Zeinab Farhat, Linda M. Liao, Maki Inoue-Choi, Erikka Loftfield

Summary: The use of multivitamins was not associated with lower all-cause mortality risk in cancer survivors, but it showed a modest inverse association for cardiovascular mortality in certain groups. Additionally, multivitamin use was linked to a lower risk of cancer-specific mortality in survivors of skin and breast cancer.

BRITISH JOURNAL OF CANCER (2023)

No Data Available